Supplementary Materials

Supplementary Material for:

A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin

Yifeng Xia, Yi-Liang Liu, Yonghua Xie, Wei Zhu, Francisco Guerra, Shen Shen, Narayana Yeddula, Wolfgang Fischer, William Low, Xiaoying Zhou, Yonghui Zhang,* Eric Oldfield,* Inder M. Verma*

*Corresponding author. E-mail: verma{at}salk.edu (I.M.V.); eoldfiel{at}illinois.edu (E.O.); zhangyonghui{at}tsinghua.edu.cn (Y.Z.)

Published 19 November 2014, Sci. Transl. Med. 6, 263ra161 (2014)
DOI: 10.1126/scitranslmed.3010382

This PDF file includes:

  • Fig. S1. Structural diagram of bisphosphonates.
  • Fig. S2. FPPS/GGPPS activity and cell growth inhibited by bisphosphonates.
  • Fig. S3. ER stress induced by blocking protein prenylation.
  • Fig. S4. Comparison of drug combinations.
  • Fig. S5. Combination therapy in KRAS-shp53 lentiviral model.
  • Fig. S6. Effect of ERK inhibition.
  • Fig. S7. Combination therapy with zoledronate and rapamycin.
  • Table S1. FPPS/GGPPS activity and cell growth inhibited by bisphosphonates.
  • Table S2. Data collection and refinement statistics.
  • Table S3. Summary of protein prenylation inhibition by various compounds.
  • Table S4. Summary of KRAS molecular weight (M.W.) measured by mass spectrometry.
  • Table S5. PCR primer sets used in the study.

[Download PDF]